About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
 Palovarotene Drug, Shows Promise in Treating Rare Hereditary Disease
Advertisement

Palovarotene Drug Shows Promise in Treating Rare Hereditary Disease

Font : A-A+

Highlights
  • Palovarotene can now suppress the formation of bony tumors in Multiple Hereditary Exostoses (MHE) patients
  • Multiple osteochondromas is a hereditary genetic disorder in which many benign bone tumors grow at active areas of bone growth
  • Multiple hereditary exostoses is a rare genetic condition that affects about 1 in 50,000 people worldwide

Palovarotene drug can now suppress or decrease bony tumor (osteochondromas) formation in Multiple Hereditary Exostoses (MHE) models found a new study published in Journal of Bone and Mineral Research journal.

The research, is an important step toward an effective pharmacological treatment for MHE, a rare genetic condition that affects about 1 in 50,000 people worldwide.

Advertisement


MHE (also known as Multiple Osteochondromas, or MO) is an inherited genetic disorder in which multiple benign bone tumors covered with cartilage grow at active areas of bone growth.

The condition is caused by mutations in two genes: EXT1 and EXT2. Individuals with these mutations develop painful, debilitating tumors, often repeatedly during their childhood and adolescence. Surgery and pain management are currently the only treatment options for MHE patients.
Advertisement

"Our study shows that palovarotene is a remarkably potent inhibitor of osteochondromas", says Yu Yamaguchi, M.D., Ph.D., a professor at SBP.

"In our mouse model of MHE, we were able to reduce bone tumors by more than 90 percent, which is a significant improvement over the previous drugs we have tested in the same mouse model." "Especially promising is that palovarotene has been tested for toxicity and side effects in humans and has been shown to be well tolerated," says Yamaguchi. "This means that timeline for getting the drug to the clinic for MHE may be shortened."

Clementia Pharmaceuticals licensed palovarotene from Roche Pharmaceuticals, which previously investigated the compound as a possible treatment for chronic pulmonary disease and evaluated its safety in more than 800 healthy volunteers and patients. Clementia Pharmaceuticals is planning to initiate a Phase 2/3 clinical trial in 2018 for patients with MHE.

"This is the first time we are seeing a clear path toward a therapy that will improve the lives of MHE patients and their families," says Sarah Ziegler, vice-president of the MHE Research Foundation.

"The long-awaited first clinical trial for a drug to treat MHE is now a reality. This breakthrough comes after years of working with medical professionals and scientists like Dr. Yamaguchi to achieve something we have all been desperately striving for, for many years."

Reference
  1. Toshihiro Inubushi, Isabelle Lemire, Fumitoshi Irie, Yu Yamaguchi. Palovarotene inhibits osteochondroma formation in a mouse model of multiple hereditary exostoses, Journal of Bone and Mineral Research (2017).DOI: 10.1002/jbmr.3341


Source: Eurekalert

Citations   close

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Rishika Gupta. (2017, November 21). Palovarotene Drug Shows Promise in Treating Rare Hereditary Disease. Medindia. Retrieved on Sep 26, 2022 from https://www.medindia.net/news/healthwatch/palovarotene-drug-shows-promise-in-treating-rare-hereditary-disease-174817-1.htm.

  • MLA

    Rishika Gupta. "Palovarotene Drug Shows Promise in Treating Rare Hereditary Disease". Medindia. Sep 26, 2022. <https://www.medindia.net/news/healthwatch/palovarotene-drug-shows-promise-in-treating-rare-hereditary-disease-174817-1.htm>.

  • Chicago

    Rishika Gupta. "Palovarotene Drug Shows Promise in Treating Rare Hereditary Disease". Medindia. https://www.medindia.net/news/healthwatch/palovarotene-drug-shows-promise-in-treating-rare-hereditary-disease-174817-1.htm. (accessed Sep 26, 2022).

  • Harvard

    Rishika Gupta. 2021. Palovarotene Drug Shows Promise in Treating Rare Hereditary Disease. Medindia, viewed Sep 26, 2022, https://www.medindia.net/news/healthwatch/palovarotene-drug-shows-promise-in-treating-rare-hereditary-disease-174817-1.htm.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
H1N1 Influenza Prevention in Children: What Parents Need to Know
Dietary Factors Responsible for Dihydrotestosterone (DHT) Production and Hair Loss
Test Your Knowledge About Chromosomes?
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Drugs Banned in India Barth Syndrome 

Most Popular on Medindia

How to Reduce School Bag Weight - Simple Tips Find a Doctor Color Blindness Calculator Nutam (400mg) (Piracetam) Accident and Trauma Care Hearing Loss Calculator Vent Forte (Theophylline) Turmeric Powder - Health Benefits, Uses & Side Effects Selfie Addiction Calculator Blood Donation - Recipients
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT ONLINE WITH A DOCTOR

×

Palovarotene Drug Shows Promise in Treating Rare Hereditary Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests